Gila Neta, PhD, MPP

Gila Neta
Program Officer
Contact:
netagil@mail.nih.gov
240-276-6785

Gila Neta, PhD, MPP is an epidemiologist and Program Officer in Implementation Science in the Office of the Director in the Division of Cancer Control and Population Sciences (DCCPS) at the National Cancer Institute (NCI). Dr. Neta serves as NCI’s primary contact for the funding announcements in Dissemination and Implementation Research in Health, and assists with research and training activities related to implementation science across the Division. She has a secondary appointment within the Epidemiology and Genomics Research Program.

Dr. Neta’s programmatic and research interests within implementation science include training, portfolio analysis, the use of PRECIS criteria in evaluating pragmatic trials, shared decision making and cancer screening, de-implementation, and the use of standardized measurement and evaluation. Dr. Neta is Co-Chair of the NIH-sponsored Annual Conference on the Science of Dissemination and Implementation. She leads the NIH D&I working group, a trans-NIH initiative providing leadership and vision for implementation science across the NIH. She also serves on the Education Committee for the American College of Epidemiology.

Prior to joining DCCPS in May 2013, Dr. Neta conducted postdoctoral epidemiologic research within the Division of Cancer Epidemiology and Genetics in the Radiation Epidemiology Branch, focusing on the potential unintended health effects of radiologic medical technologies. Dr. Neta received her Master of Public Policy degree at the University of California at Berkeley in 2001, and her Doctorate in Epidemiology from Johns Hopkins University Bloomberg School of Public Health in 2009. She conducted her doctoral dissertation work at the Eunice Kennedy Shriver National Institute for Child Health and Human Development.


Select Publications


Interests

  • Implementation science and epidemiology
  • Dissemination and implementation (D&I) portfolio analysis
  • D&I training
  • Pragmatic trials and use of PRECIS-2
  • De-implementation